Equities

OptiNose Inc

OptiNose Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7956
  • Today's Change-0.054 / -6.40%
  • Shares traded1.81m
  • 1 Year change-37.35%
  • Beta-0.0192
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7494111
Total Receivables, Net203435
Total Inventory8.059.4412
Prepaid expenses3.672.872.57
Other current assets, total----0.01
Total current assets105140160
Property, plant & equipment, net2.293.245.40
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.110.500.29
Total assets108144166
LIABILITIES
Accounts payable3.895.298.01
Accrued expenses424551
Notes payable/short-term debt1301290
Current portion long-term debt/capital leases------
Other current liabilities, total------
Total current liabilities17717959
Total long term debt00126
Total debt130129126
Deferred income tax------
Minority interest------
Other liabilities, total18222.19
Total liabilities194201188
SHAREHOLDERS EQUITY
Common stock0.110.110.08
Additional paid-in capital634628588
Retained earnings (accumulated deficit)(720)(685)(610)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.08)(0.08)(0.08)
Total equity(87)(57)(22)
Total liabilities & shareholders' equity108144166
Total common shares outstanding11211182
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.